All News

As the first immunotherapy option in this setting, the approval sets a new standard for resectable early-stage gastric and gastroesophageal junction (GEJ) cancers.

A study reveals real-world effects of switching to adalimumab biosimilar Hyrimoz, highlighting flare rates and injection pain concerns in inflammatory disease patients.

Pirtobrutinib is now fully approved for CLL/SLL in those previously treated with Bruton tyrosine kinase inhibitors.

Jennifer Graff, PharmD, and Brian Reid, MS, emphasize that DTC pharmacy models can give patients more convenient access to medications but may increase out-of-pocket costs.

New research shows that those with dry eye need more than 20 blinks per minute to maintain their tear film.

A new study shows fee-for-service care is linked to higher odds of low-value surgery, suggesting salaried models may reduce unnecessary procedures.

Avoiding losses of coverage due to administrative barriers can be done with a focus on making some of the processes automatic.

The guidelines highlight the need for lifelong obesity management, early diagnosis, comorbidity prevention, and patient-centered care.

Expert insights help define the complexities of seasonal affective disorder, its unique symptoms, and effective treatment strategies.

New research shows immigrant children face higher odds of unmet medical needs as federal and state coverage rules narrow.

Adalimumab significantly reduces activity limitations and boosts work ability and quality of life in patients with psoriasis.

McKesson's report highlights key trends in community oncology, emphasizing patient-centered care, precision medicine, and the need for innovative clinical trials.

FDA has granted sonrotoclax priority review for relapsed mantle cell lymphoma, showcasing promising trial results.

Screening among 45- to 49-year-olds rose nearly 10-fold in hospitals after US guideline updates, but disparities persist.

Experts explore advancements in telehealth and precision medicine, addressing cancer care gaps for rural and underserved populations in oncology.

Lenacapavir and cabotegravir are among the most important advancements in HIV prevention and treatment within the past 10 years.

New research reveals that total social media use does not significantly impact adolescents' body image concerns, challenging previous assumptions.

Olutasidenib shows promising long-term efficacy and safety in treating relapsed or refractory mutant IDH1 acute myeloid leukemia.

Global chronic lymphocytic leukemia incidence and mortality is declining, but the disease’s prevalence has increased modestly.

New research shows patients commonly take lower doses of nintedanib, and the majority are also taking immunomodulatory drugs.

Elevated levels of a combined biomarker integrating CRP, triglycerides, and glucose are associated with increased risk of rheumatoid arthritis.

In real-world usage, 97% of cases of cytokine release syndrome following treatment with lisocabtagene maraleucel happened within 15 days of infusion.

Pretransplant NPM1 MRD testing significantly predicts relapse risk in acute myeloid leukemia.

ATTRibute-CM data show acoramidis reduced mortality in ATTRwt-CM and ATTRv-CM and raised serum transthyretin through 42 months.

Over 50% of patients with high-grade serous ovarian cancer (HGSOC) had surgery, often decades before diagnosis, where salpingectomy could have reduced risk.

Phase 3 OCEANIC-STROKE data show how asundexian offers a potential new secondary stroke prevention option.

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, achieving significant symptom reduction and demonstrating a novel CAR T-cell approach.

Altered expression across multiple ncRNA classes consistently correlates with inferior OS, PFS, and TTT in nearly 5000 patients.